Sugi Predict

Sugi Predict / Compounds / SCHEMBL3090863

SCHEMBL3090863

SCHEMBL3090863

CCCCC(CCC)CCCCO

nearest known ligand 0.52

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.52
▸ ALDH1A1 P00352 5/20 0.52
▸ LMNA P02545 3/20 0.52
▸ TSHR P16473 3/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.41
▸ CYP3A4 P08684 1/20 0.39
▸ CA2 P00918 2/20 0.38
▸ DNM1 Q05193 1/20 0.35
▸ FDPS P14324 1/20 0.34
▸ SPHK1 Q9NYA1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16896968 1.00 SMN1; SMN2 (0.52) SMN1; SMN2ALDH1A1LMNATSHRHSD17B10
SCHEMBL16548258 1.00 SMN1; SMN2 (0.52) SMN1; SMN2ALDH1A1LMNATSHRHSD17B10
SCHEMBL6440790 0.98 LMNA (0.56) SMN1; SMN2ALDH1A1LMNATSHRHSD17B10
SCHEMBL2048459 0.95 SMN1; SMN2 (0.60) SMN1; SMN2ALDH1A1LMNATSHRHSD17B10
SCHEMBL1100934 0.95 SMN1; SMN2 (0.58) SMN1; SMN2ALDH1A1LMNATSHRHSD17B10
SCHEMBL6440890 0.95 LMNA (0.50) SMN1; SMN2ALDH1A1LMNATSHRHSD17B10
SCHEMBL6446817 0.95 SMN1; SMN2 (0.58) SMN1; SMN2ALDH1A1LMNATSHRHSD17B10
SCHEMBL1099125 0.95 LMNA (0.50) SMN1; SMN2ALDH1A1LMNATSHRHSD17B10
SCHEMBL3098238 0.93 LMNA (0.62) SMN1; SMN2ALDH1A1LMNATSHRHSD17B10
SCHEMBL4920668 0.93 LMNA (0.62) SMN1; SMN2ALDH1A1LMNATSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024071281-A1 ASYMMETRIC ALLYL FLUORIDE COMPOUND AND METHOD FOR PRODUCING SAME シンクレスト株式会社 2024-04-04 — — WO disclosed
WO-2023243699-A1 AMINO ACID HAVING FLUORINE AT α-POSITION, AND DERIVATIVE OF SAME シンクレスト株式会社 2023-12-21 — — WO disclosed
WO-2023234187-A1 METHOD FOR PRODUCING ORGANIC COPPER COMPOUND シンクレスト株式会社 2023-12-07 — — WO disclosed
WO-2023120647-A1 ORGANIC COPPER COMPOUND, AND METHOD FOR PRODUCING ORGANIC COPPER COMPOUND シンクレスト株式会社 2023-06-29 — — WO disclosed
WO-2023120645-A1 ORGANIC ZINC COMPOUND AND PRODUCTION METHOD FOR ORGANIC ZINC COMPOUND シンクレスト株式会社 2023-06-29 — — WO disclosed
CN-213375196-U Low-energy-consumption methanol rectification system 陕西聚能新创煤化科技有限公司 2021-06-08 — — CN disclosed
US-10000432-B2 Processes for the synthesis of chiral 1-alkanols PURDUE RESEARCH FOUNDATION (US) 2018-06-19 — — US disclosed
US-20160332940-A1 PROCESSES FOR THE SYNTHESIS OF CHIRAL 1-ALKANOLS PURDUE RESEARCH FOUNDATION (US) 2016-11-17 — — US disclosed
US-20100279963-A1 DICARBONYL DERIVATIVES AND METHODS OF USE ABRAXIS BIOSCIENCE, LLC (US) 2010-11-04 — — US disclosed
US-7799954-B2 Dicarbonyl derivatives and methods of use ABRAXIS BIOSCIENCE, LLC (US) 2010-09-21 — — US disclosed
EP-0460950-B1 Radicicol derivatives, their preparation and their anti-tumour activity SANKYO CO (JP) 1997-03-05 — — EP disclosed
US-5597846-A ESTERS OF RADICICOL SANKYO COMPANY, LIMITED (JP) 1997-01-28 — — US disclosed
US-5559109-A Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist SANKKO COMPANY, LIMITED (JP) 1996-09-24 — — US disclosed
US-5556852-A PLATELET ACTIVATING FACTOR ANTAGONISTS SANKYO COMPANY, LIMITED (JP) 1996-09-17 — — US disclosed
EP-0395446-B1 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists SANKYO CO (JP) 1995-03-01 — — EP disclosed
US-5369106-A N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists SANKYO COMPANY, LIMITED (JP) 1994-11-29 — — US disclosed
US-5192766-A Platelet activating factor antagonist SANKYO COMPANY, LIMITED (JP) 1993-03-09 — — US disclosed
WO-1991018905-A1 RADICICOL DERIVATIVES, THEIR PREPARATION AND THEIR ANTI-TUMOR ACTIVITY SANKYO COMPANY LIMITED (JP) 1991-12-12 — — WO disclosed
EP-0460950-A1 Radicicol derivatives, their preparation and their anti-tumour activity Sankyo Company Limited (JP) 1991-12-11 — — EP disclosed
EP-0395446-A2 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists Sankyo Company Limited (JP) 1990-10-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160332940-A1 PROCESSES FOR THE SYNTHESIS OF CHIRAL 1-ALKANOLS CYP51A1, ALKBH3, ALKBH1 SMN1; SMN2 4633/4885ALDH1A1 500/4885LMNA 3812/4885
US-20100279963-A1 DICARBONYL DERIVATIVES AND METHODS OF USE AADAC, DCK, MLYCD SMN1; SMN2 3902/4885ALDH1A1 1688/4885LMNA 2382/4885
US-10000432-B2 Processes for the synthesis of chiral 1-alkanols CYP51A1, ALKBH3, ALKBH1 SMN1; SMN2 4633/4885ALDH1A1 500/4885LMNA 3812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.